Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

NCT01324232 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

209

Enrollment

INDUSTRY

Sponsor class

Conditions

Central Neuropathic Pain
Multiple Sclerosis

Interventions

DRUG: AVP-923-45
DRUG: AVP-923-30
DRUG: AVP-923-20
DRUG: Placebo

Sponsor

Avanir Pharmaceuticals